PEDIATRICS Vol. 99 No. 2 February 1997, pp. 282-288 (doi:10.1542/peds.99.2.282)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 99 No. 2 February 1997, pp. 282-288

AMERICAN ACADEMY OF PEDIATRICS:
Acellular Pertussis Vaccine: Recommendations for Use as the Initial Series in Infants and Children

Committee on Infectious Diseases

In 1991 and 1992, the US Food and Drug Administration approved two acellular pertussis vaccines combined with diphtheria and tetanus toxoids for use as the fourth and fifth doses after the initial three-dose primary series with the standard whole-cell pertussis vaccine administered at 2, 4, and 6 months of age. Recently completed trials of acellular pertussis vaccines conducted in Europe have documented the efficacy of these vaccines when administered as a primary series in infancy. Based on these studies, two acellular pertussis vaccines, Tripedia (Connaught Laboratories, Swiftwater, PA) and ACEL-IMUNE (Wyeth-Lederle Laboratories, Pearl River, NY), were licensed by the Food and Drug Administration for the initial three-dose series. Additional acellular pertussis vaccines are likely to be licensed for use in infants in the future. The recommendations in this statement supplement previous American Academy of Pediatrics guidelines for the use of acellular pertussis vaccines.




This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
P. H. Dennehy
Active Immunization in the United States: Developments over the Past Decade
Clin. Microbiol. Rev., October 1, 2001; 14(4): 872 - 908.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
M. Pourcyrous, S. B. Korones, D. Crouse, and H. S. Bada
Interleukin-6, C-Reactive Protein, and Abnormal Cardiorespiratory Responses to Immunization in Premature Infants
Pediatrics, March 1, 1998; 101 (3): e3 - e3.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
L. K. Ball, G. Evans, and A. Bostrom
Risky Business: Challenges in Vaccine Risk Communication
Pediatrics, March 1, 1998; 101(3): 453 - 458.
[Full Text] [PDF]